Incidence and Potential Mechanism(s) of  Post-Procedural Rise of Cardiac Biomarker  in @entity1 With Coronary Artery  Narrowing After Implantation of an  XXXX -Eluting Bioresorbable Vascular Scaffold or @entity2239 -Eluting Metallic Stent.

@entity1 @entity296 @entity908 @entity2239 @entity951 @entity741 @entity583
OBJECTIVES: This study sought to evaluate the mechanism of post-procedural cardiac biomarker (CB) rise following device implantation. BACKGROUND: A fully bioresorbable Absorb scaffold, compared with @entity2239 -eluting metallic stents (EES), might  be associated with a higher incidence of periprocedural @entity296 . METHODS: In 501 @entity1 with stable or unstable @entity951 randomized to either Absorb (335 @entity1 ) or EES (n = 166) in the ABSORB II trial, 3 types of CB ( @entity908 kinase, @entity908 kinase-myocardial band, and troponin) were  obtained before and after procedure. Per protocol, periprocedural @entity583 (PMI) was defined as @entity908 kinase rise >2* the upper limit of normal with @entity908 kinase-myocardial band rise. RESULTS: Incidence of side branch occlusion and any anatomic complications assessed by angiography was similar between the 2 treatment arms (side branch occlusion: Absorb: 5.3% vs. Xience: 7.6%, p  = 0.07; any anatomic complication: Absorb: 16.4% vs. EES: 19.9%, p  = 0.39). Fourteen @entity1 who presented with recent  @entity583 at entry with normalized @entity908 kinase-myocardial band according to the protocol were excluded for post-CB analysis. The overall compliance for CB was 97.8%. The CB rise subcategorized in 7  different ranges was comparable between the 2 treatment arms. PMI rate was numerically higher in the Absorb  arm according to the per-protocol definitions, and treatment with overlapping devices was the only independent determinant of per-protocol PMI (odds ratio: 5.07, 95% confidence interval: 1.78 to 14.41, p  =  0.002). CONCLUSIONS: There were no differences in the incidence of CB rise and PMI between Absorb and EES. Device overlap might be a precipitating factor of @entity296 . (ABSORB II Randomized Clinical Trial: A Clinical Evaluation to Compare the Safety, Efficacy, and Performance of Absorb @entity2239 Eluting Bioresorbable Vascular Scaffold System Against Xience @entity2239 Eluting Coronary Stent System in the Treatment of Subjects With @entity741 Caused by De Novo Native Coronary Artery Lesions [ABSORB II]; NCT01425281).
